Global Competitiveness in Pharmaceuticals: A European Perspective

Gambardella, Alfonso and Orsenigo, Luigi and Pammolli, Fabio (2000): Global Competitiveness in Pharmaceuticals: A European Perspective. Published in: DG Enterprise, European Commission (2001)

Abstract

The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US. Over the last two decades, the industry has experienced some important structural changes, mainly driven by technological and institutional shocks that have affected all the stages of its value chain. In turn, this has led to changes in firms' organisation and in market structure, within domestic markets, regionally, and globally. The main finding of the report is that the European industry has indeed been losing competitiveness as compared to the USA, although there are large differences and trends across European countries. As a whole, Europe is lagging behind in its ability to generate, organise, and sustain innovation processes that are increasingly expensive and organisationally complex. In fact, one conclusion of the report is that the relative position of the US as a locus of innovation in pharmaceuticals has increased over the past decade compared to Europe. All in all, the report claims that the competitiveness of the European pharmaceutical industry is negatively affected by the persistence of insufficient degrees of competition and institutional integration, still centred on domestic and fragmented health care and research systems. Four sets of variables have been found to be relevant as sources of competitiveness and growth in pharmaceuticals: 1) The size and the structure of the biomedical education and research systems; 2) Some basic institutions governing labor markets for skilled researchers and managers, as well as corporate governance and finance; 3) Intellectual property rights and patent law; 4) The institutional settings in the regulation of health care systems and, moreover, the nature and intensity of competition on the final market. The data analysed in this report come from OECD, Eurostat, the European Patent Office, IMS Health and PHID (PHarmaceutical Industry Database) at the University of Siena.

• Item Type: MPRA Paper
• Language: English
• Keywords: Pharmaceutical Industry, R&D, Innovation, Competitiveness
• Subjects: L - Industrial Organization > L6 - Industry Studies: Manufacturing > L65 - Chemicals ; Rubber ; Drugs ; Biotechnology; L - Industrial Organization > L1 - Market Structure, Firm Strategy, and Market Performance > L16 - Industrial Organization and Macroeconomics: Industrial Structure and Structural Change ; Industrial Price Indices; D - Microeconomics > D2 - Production and Organizations > D23 - Organizational Behavior ; Transaction Costs ; Property Rights; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O32 - Management of Technological Innovation and R&D; D - Microeconomics > D2 - Production and Organizations > D24 - Production ; Cost ; Capital ; Capital, Total Factor, and Multifactor Productivity ; Capacity; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O31 - Innovation and Invention: Processes and Incentives

References

Abramowitz M., 1986: “Catching Up, Forging Ahead, and Falling Behind”, Journal of Economic History, vo. 46, pp. 385-406.

Arora A., Gambardella A., Pammolli F., Riccaboni M., 2000: “The Nature and the Extent of the Market for Technology in Biopharmaceuticals”, paper prepared for the International Conference on Technology Policy and Innovation, Paris.

Arora, A., Fosfuri, A., Gambardella, A., 2000: “Markets for Technology”, manuscript, Carnegie Mellon University, Pittsburgh, USA. Arora, A., Gambardella, A., 1994: “The Changing Technology of Technical Change: General and Abstract Knowledge and the Division of Innovative Labor”, Research Policy, 23, 5, pp. 523-532.

Arrow K.J., 1983: “Innovation in Large and Small Firms”, in Ronen J., ed., Entrepreneurship, Lexington Books, Lexington, Ma.

Audretsch D. B., Stephan P., 1996: “Company-Scientist Locational Linkages: The Case of Biotechnology”, American Economic Review, vol. 86, pp. 641-652.

Bank of England, 1996: “The Financing of Technology-Based Small Firms”, Bank of England, London.

Barnett R., et al., 1998: “Biotechnology in Germany. Report of an ITS Expert Mission”, British Embassy, Bonn.

Bottazzi G., G. Dosi, F. Pammolli, M. Riccaboni, 2000: “Innovation and corporate growth in the evolution the pharmaceutical industry”. International Journal of Industrial Organization, 19 (7), 1161-1187.

Branscomb L. M., Keller J. H., eds., 1998: “Investing in Innovation”, The MIT Press, Cambridge, Ma.

Braun D., 1994: “Structure and Dynamics of Health research and Public Funding: An International Institutional Comparison, Kluwer Academic Publishers, Amsterdam, The Netherlands.

Burstall, M.L., 1985: “The Community's pharmaceutical industry”, Commission of the European Communities, Bruxelles.

BVK, 1994-1998: “Venture Capital in Europe”, BVK Nachrichten Special Report.

Casper S., Kettler H., 2000: “The Road to Sustainability in the UK and German Biotechnology Industries”, ESSY project, mimeo.

Congressional Budget Office, 1998: “How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry”, Congressional Budget Office, US Congress, Washington DC.

Cockburn, I., Henderson R., 1996: “Public-Private Interaction in Pharmaceutical Research”, Proceedings of the National Academy of Sciences, 93/23, November, p.12725-12730.

Cohen W., Levinthal D., 1989: “Absorptive Capacity: A New Perspective on Learning and Innovation”, Administrative Science Quarterly, vol. 35, pp. 128-152.

Council on Competitiveness, 1998: “Going Global: The New Shape of American Competitiveness, Council on Competitiveness, Washington DC.

Dasgupta P., David P. A., 1994: “The New Econonomics of Science”, Research Policy, 23, 5.

Danzon P., 1996: “Pharmaceutical Price Regulation”, AEI, Washington DC.

Davies S.W., Lyons B.R., 1996: “Industrial Organisation in the European Union”, Oxford University Press, Oxford.

Deutsche Bank Research, 1999: “German Biotech: New Stars in the Universe”, Deutsche Bank Research German Equities Biotechnology Group, April 27.

Dosi G., 1999: “Some Notes on National Systems of Innovation and Production, and their Implications for Economic Analysis”, in Archibugi D., Howells J., Michie J., eds., Innovation Policy in a Global Economy, Cambridge University Press, Cambridge, pp. 35-48.

Dosi, G., 1988: “Sources, Procedures and Microeconomic Effects of Innovation”, Journal of Economic Literature, 26, pp. 1120-1171.

Drews J., 2000: “Drug Discovery: A Historical Perspective”, Science, vol. 287, pp.1960-64.

DTI, 1999: “Genome Valley Report. The Economic Potential and Strategic Importance of Biotechnology in the UK”, Department of Trade and Industry, London.

EFPIA, 2000: “The Pharmaceutical Industry in Figures”, The European Federation of Pharmaceutical Industries and Associations, Bruxelles.

Eisenberg R., 1996: “Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored Research”, Virginia Law Review,vol. 82, pp. 1663-1727.

EIU, 1999: “The Prospects for Private HealthCare in Europe”, Economist Intelligence Unit, London.

Ernst&Young, 2000: “European Life Sciences 2000”, Ernst&Young International, London.

European Commission, 1997: “Agenda 2000”, European Commission, Brussels.

European Commission, “Panorama of the EU industry”, various years, Brussels.

Galambos, L., Sturchio, J., 1996: “The Pharmaceutical Industry in the Twentieth Century: a Reappraisal of the Sources of Innovation, History and Technology, 13, 2, pp. 83-100.

Galambos, L., Sturchio, J., 1998: “Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation”, Business History Review, LXXII, pp. 250-278.

Gambardella, A., 1995: “Science and Innovation in the US Pharmaceutical Industry”, Cambridge, Cambridge University Press.

Gambardella A., Orsenigo L., Pammolli F., 2000: “Benchmarking the Competitiveness of the European Pharmaceutical Industry”, European Commission, Brussels.

General Accounting Office, 2000: “Adapting Private Sector Management Methods for a Medicare Benefit”, United States General Accounting Office, May 11, Washington DC.

Grabowski H., Vernon J., 1983: “The regulation of pharmaceuticals”, American Enterprise Institute for Public Policy Research, Washington and London.

Grabowski H., Vernon J., 1987: “Longer Patents for Lower Imitation Barriers: The 1984 Drug Act”, American Economic Review Papers and Proceedings, May, 195-198.

Grabowski H., Vernon, J., 1994: “Innovation and structural change in pharmaceuticals and biotechnology”, Industrial and Corporate Change, vol.3, n.2.

Griliches Z., 1990: “Patent Statistics as Economic Indicators: A Survey”, Journal of Economic Literature, vol. 28, pp. 1661-1707.

Hancher L., 1990: “Regulating for Competition: Government, Law and the Pharmaceutical Industry in the United Kingdom and France”, Oxford, Oxford University Press.

Hellerstein J., 1998: “The Importance of the Physician in the Generic versus Trade-Name Prescription Decision”, RAND Journal of Economics, vol. 29, n. 1, pp. 108-136.

Helms R., ed., 1996: “Competitive Strategies in the Pharmaceutical Industry”, AEI,Washington DC.

Helpman R., ed., 1998: “General Purpose Technologies”, MIT Press, Cambridge Ma.

Henderson R., Cockburn I., 1996: “Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery, Rand Journal of Economics, Spring, 27(1), pp. 32-59.

Henderson, R., Orsenigo, L., Pisano, G. P., 1999: “The Pharmaceutical Industry and the Revolution in Molecular Biology: Exploring the Interactions between Scientific, Institutional and Organizational Change, in Mowery D.C.”, Nelson R.R., eds., Sources of Industrial Leadership, Cambridge University Press, Cambridge.

Jacobzone S., 2000: “Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals”, Labour Market and Social Policy Occasional Papers, n.40, OECD, Paris.

Jaffe A. B., Trajtenberg M., Henderson R., 1993: “Geographic Localization of Knowledge Spillovers as Evidenced by Patent Citations”, Quarterly Journal of Economics, August.

Jorgenson D. W., Griliches Z., 1967: “The explanation of Productivity Change”: Review of Economic Studies, Vol. 34, n. 3, July, pp. 249-283.

Landau R., Taylor T., Wright G., eds., 1996: “The Mosaic of Economic Growth”, Stanford University Press, Stanford, Ca.

March J., 1991: “Exploration and Exploitation in Organizational Learning”, Organization Science, vol. 1, n. 2, pp. 71-87.

Matraves C., 1999: “Market Structure, R&D, and Advertising in the Pharmaceutical Industry”, The Journal of Industrial Economics, vol. XLVIII, n. 2, pp. 169-194.

Mc Kelvey, M., 1995: “Evolutionary Innovation: The Business of Biotechnology”, Oxford University Press, Oxford.

McMillan G.S., Narin F., Deeds L., 2000: “An analysis of the critical role of publicscience in innovation: The Case of Biotechnology”, Research Policy, vol. 29, pp. 1-8.

Merges R., Nelson R.R., 1994: “On Limiting or Encouraging rivalry in Technical progress: The Effect of Patent Scope Decisions”, Journal of Economic Behavior and Organization, Vol. 25, 1-24.

MERIT, 1996: "The Organization of innovative activities in the European Biotechnology Industry and its implications for future Competitiveness", Report for the European Commission, Maastricht.

Mitchell W., Roehl T., Slattery, R. J. 1995: “Influences on R&D Growth among Japanese Pharmaceutical Firms, 1975-1990, Journal of High Technology Management Research, Vol.6, N.1, 17-31.

Mowery D., 1998: “The Changing Structure of the US National Innovation System: Implications for International Conflict and Cooperation in R&D Policy”, Research Policy, vol. 27, pp. 639-654.

Mowery D., Nelson R.R., eds., 1999: “Sources of Industrial Leadership”, Cambridge University Press, Cambridge.

Mowery D., Rosenberg N., 1993: “The US National Innovation System, in Nelson R.R., ed., National Innovation Systems: A Comparative Analysis”, Oxford University Press, Oxford.

Mowery, D., 1997: “Market Failure or Market Magic? Structural Change in the U.S. National Innovation System”, OECD meeting on “Best Practices in Technology and Innovation Policy”, Paris.

National Research Council, 2000: “US Industry in 2000, Board on Science, Technology, and Economic Policy”, National Research Council, Washington DC.

Nelson R.R., 1996: “The Sources of Economic Growth”, Harvard University Press, Cambdridge, Ma.

Nelson R.R., ed., 1993: “National Systems of Innovation”, Oxford, Oxford UniversityPress.

NERA, 1998: “Policy Relating to Generic Medicines in the OECD”, National Economic Research Associates, London.

Newhouse J., 1993: “Free for All? Lessons from the RAND Insurance Experiment”, Harvard University Press, Cambridge, Ma.

OECD, 1996: “Globalisation in the Pharmaceutical Industry”, Paris, OECD.

OECD, 1997: “Financing Innovation in Health Care”, OECD, Paris.

OECD, 1999: “Health Data”, OECD, Paris.

OECD, 2000: “Foreign Trade by Commodities”, OECD, Paris.

Orsenigo L., 1989: “The Emergence of Biotechnology”, London, Pinter Publishers.

Orsenigo L., F. Pammolli, M. Riccaboni, 2000: “Technological Change and Network Dynamics”, Research Policy, forthcoming

Orsenigo L., F. Pammolli, M. Riccaboni, et al., 1999: “The dynamics of knowledge and the evolution of an industry network. Lessons from pharmaceuticals”, Journal of Management and Governance, vol. 1, n. 2.

OTA, 1993: “Pharmaceutical R&D: Costs, Risks, and Rewards”, Office of Technology Assessment, Washington DC.

Pammolli F., Magazzini L., Riccaboni M., 2000: “On the Effects of Competition after Patent Expiration in Pharmaceuticals”, EPRIS Working Paper.

Pammolli F., Orsenigo L., Riccaboni M., 2000: “Technological Paradigms, and the Nature of Markets for Technology”, in Pagano U., Nicita A., 2000, The Evolution of Economic Diversity, Routledge, London.

Pammolli F., Riccaboni M., Baio G., 2000: “On Division of Innovative Labor and Markets for Technologies. Lessons from the Pharmaceutical Industry”, EPRIS working paper.

Pavitt K., 1998: “The inevitable limits of EU R&D funding”, Research Policy, vol. 27, pp. 559-568.

PhRMA, 2000: “Pharmaceutical Industry Profile”, PhRMA, Washington DC.

Powell, W. W., Doput, K. W., Smith-Doerr, L., 1996: “Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology”, Administrative Science Quarterly, 41, pp. 116-145.

Saxenian A., 1994: “Regional Advantage”, Harvard University Press, Cambridge, Ma.

Schwartzman D., 1976: “Innovation in the Pharmaceutical Industry”, Johns Hopkins University Press, Baltimore.

Scriabine A., 1999: “The role of biotechnology in drug development”, in Landau R., Achilladelis B., Scriabine A. (eds.) Pharmaceutical Innovation, Chemical Heritage Foundation, Philadephia.

SERD, 1996: “The Role of SMEs in Technology Creation and Diffusion: Implications for European Competitiveness in Biotechnology”, Report for the European Commission, Maastricht.

Soskice D., 1997: “German Technology Policy, Innovation, and National Institutional Frameworks”, Industry and Innovation, 4, pp. 75-96.

Stokes D. E., 1997: “Pasteur’s Quadrant”, Brookings Institution Press, Washington DC.

Sutton J., 1998: “Technology and Market Structure: Theory and History”, MIT Press, Cambridge.

Thomas, L.G., 1994: “Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals”, Industrial and Corporate Change, Vol.3, n.2, 1994.

US Senate, 1993: “Pharmaceutical Marketplace Reform: Is Competition the Right Prescription?”, Hearing Before the Special Committee on Ageing, United States Senate, November 16, Washington DC.

USITC, 1991: “Global Competitiveness of U.S. Advanced-Technology Manufacturing Industries: Pharmaceuticals”, U.S. International Trade Commission, Office of Industries, Washington DC.

USITC, 1999: “Review of the Global Competitiveness in the Pharmaceutical Industry”, U.S. International Trade Commission, Office of Industries, Staff Research Study, Washington DC.

Ward M., Dranove D., 1995: “The Vertical Chain of R&D in the Pharmaceutical Industry”, Economic Inquiry, Vol. 33, January 1995, p 1-18.

World Health Organization Europe, 1997: “European Health Care Reform”, WHO Regional Publications, European Series, n. 72.

Zucker L., Darby M., Armstrong J., 1998: “Geographically localized knowledge: Spillovers or markets?”, Economic Inquiry, 36, January, p 65-86.

Zucker L., Darby M., Brewer M., 1997: “Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises”, American Economic Review, June 1997, v. 87, n. 3.

Zysman J., 1994: “How Institutions Create Historically Rooted Trajectories of Growth”, Industrial and Corporate Change, vol. 3, pp. 243-283.